Phylogeny and molecular evolution of the hepatitis C virus

Infection, Genetics and Evolution

Volumn 21, Issue , 2014, Pages 67-82

  Jackowiak, Paulina ^a   Kuls, Karolina ^b   Budzko, Lucyna ^a   Mania, Anna ^b   Figlerowicz, Magdalena ^b   Figlerowicz, Marek ^a,c  

^a INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c POZNAN UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Evolution; HCV; Phylogeny

Indexed keywords

PEGINTERFERON ALPHA; RIBAVIRIN; VIRUS RNA;

ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; FOUNDER EFFECT; GENETIC RECOMBINATION; GENETIC SELECTION; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MOLECULAR EVOLUTION; NONHUMAN; NUCLEOTIDE SEQUENCE; ONSET AGE; PHYLOGENY; POINT MUTATION; PRIORITY JOURNAL; REVIEW; VIRUS CELL INTERACTION; VIRUS CHARACTERIZATION; VIRUS MUTATION; VIRUS PATHOGENESIS; VIRUS REPLICATION; CLASSIFICATION; GENETICS; GENOTYPE; HEPACIVIRUS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; PHYLOGEOGRAPHY; VIROLOGY; VIRUS GENOME;

HEPATITIS C VIRUS; RNA VIRUSES;

EVOLUTION, MOLECULAR; GENETIC VARIATION; GENOME, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HOST-PATHOGEN INTERACTIONS; HUMANS; PHYLOGENY; PHYLOGEOGRAPHY;

EID: 84888060781     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2013.10.021     Document Type: Review

References (208)

1. Abe H., Hayes C.N., Hiraga N., Imamura M., Tsuge M., Miki D., Takahashi S., Ochi H., Chayama K. A translational study of resistance emergence using sequential direct-acting antiviral agents for hepatitis C using ultra-deep sequencing. Am. J. Gastroenterol. 2013, 108:1464-1472.
2. Abe K., Inchauspe G., Fujisawa K. Genomic characterization and mutation rate of hepatitis C virus isolated from a patient who contracted hepatitis during an epidemic of non-A, non-B hepatitis in Japan. J. Gen. Virol. 1992, 73(Pt 10):2725-2729.
3. Adiwijaya B.S., Herrmann E., Hare B., Kieffer T., Lin C., Kwong A.D., Garg V., Randle J.C., Sarrazin C., Zeuzem S., Caron P.R. A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. PLoS Comput. Biol. 2010, 6:e1000745.
4. Afdhal N., O'Brien C., Godofsky E., Rodriguez-Torres M., Pappas S.C., Lawitz E., Pockros P., Sulkowski M., Jacobson I., Chao G., Knox S., Pietropaolo K., Brown N.A. Valopicitabine (NM283), alone or with peginterferon, compared to peg interferon/ribavirin (pegIFN/RBV) retreatment in patients with HCV-1 infection and prior non-response to pegIFN/RBV: one-year results. J. Hepatol. 2007, 46:S5.
5. Akuta N., Suzuki F., Seko Y., Kawamura Y., Sezaki H., Suzuki Y., Hosaka T., Kobayashi M., Hara T., Saitoh S., Arase Y., Ikeda K., Kumada H. Emergence of telaprevir-resistant variants detected by ultra-deep sequencing after triple therapy in patients infected with HCV genotype 1. J. Med. Virol. 2013, 85:1028-1036.
6. Alejska M., Malinowska N., Urbanowicz A., Figlerowicz M. Two types of non-homologous RNA recombination in brome mosaic virus. Acta Biochim. Pol. 2005, 52:833-844.
7. Alizon S., Luciani F., Regoes R.R. Epidemiological and clinical consequences of within-host evolution. Trends Microbiol. 2011, 19:24-32.
8. Allain J.P., Dong Y., Vandamme A.M., Moulton V., Salemi M. Evolutionary rate and genetic drift of hepatitis C virus are not correlated with the host immune response: studies of infected donor-recipient clusters. J. Virol. 2000, 74:2541-2549.
9. Allen T.M., Altfeld M., Geer S.C., Kalife E.T., Moore C., O'Sullivan K.M., Desouza I., Feeney M.E., Eldridge R.L., Maier E.L., Kaufmann D.E., Lahaie M.P., Reyor L., Tanzi G., Johnston M.N., Brander C., Draenert R., Rockstroh J.K., Jessen H., Rosenberg E.S., Mallal S.A., Walker B.D. Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution. J. Virol. 2005, 79:13239-13249.
10. Amoroso P., Rapicetta M., Tosti M.E., Mele A., Spada E., Buonocore S., Lettieri G., Pierri P., Chionne P., Ciccaglione A.R., Sagliocca L. Correlation between virus genotype and chronicity rate in acute hepatitis C. J. Hepatol. 1998, 28:939-944.
11. Arenas J.I., Gallegos-Orozco J.F., Laskus T., Wilkinson J., Khatib A., Fasola C., Adair D., Radkowski M., Kibler K.V., Nowicki M., Douglas D., Williams J., Netto G., Mulligan D., Klintmalm G., Rakela J., Vargas H.E. Hepatitis C virus quasi-species dynamics predict progression of fibrosis after liver transplantation. J. Infect. Dis. 2004, 189:2037-2046.
12. Bacon B.R., Gordon S.C., Lawitz E., Marcellin P., Vierling J.M., Zeuzem S., Poordad F., Goodman Z.D., Sings H.L., Boparai N., Burroughs M., Brass C.A., Albrecht J.K., Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011, 364:1207-1217.
13. Barr J.N., Fearns R. How RNA viruses maintain their genome integrity. J. Gen. Virol. 2010, 91:1373-1387.
14. Bartenschlager R., Lohmann V. Replication of hepatitis C virus. J. Gen. Virol. 2000, 81:1631-1648.
15. Bartenschlager R., Lohmann V., Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat. Rev. Microbiol. 2013, 11:482-496.
16. Bernardin F., Herring B., Page-Shafer K., Kuiken C., Delwart E. Absence of HCV viral recombination following superinfection. J. Viral Hepatitis 2006, 13:532-537.
17. Bittar C., Jardim A.C., Yamasaki L.H., de Queiroz A.T., Carareto C.M., Pinho J.R., de Carvalho-Mello I.M., Rahal P. Genetic diversity of NS5A protein from hepatitis C virus genotype 3a and its relationship to therapy response. BMC Infect. Dis. 2010, 10:36.
18. Boeras D.I., Hraber P.T., Hurlston M., Evans-Strickfaden T., Bhattacharya T., Giorgi E.E., Mulenga J., Karita E., Korber B.T., Allen S., Hart C.E., Derdeyn C.A., Hunter E. Role of donor genital tract HIV-1 diversity in the transmission bottleneck. Proc. Natl. Acad. Sci. USA 2011, 108:E1156-1163.
19. Bouchardeau F., Cantaloube J.F., Chevaliez S., Portal C., Razer A., Lefrere J.J., Pawlotsky J.M., De Micco P., Laperche S. Improvement of hepatitis C virus (HCV) genotype determination with the new version of the INNO-LiPA HCV assay. J. Clin. Microbiol. 2007, 45:1140-1145.
20. Bull R.A., Luciani F., McElroy K., Gaudieri S., Pham S.T., Chopra A., Cameron B., Maher L., Dore G.J., White P.A., Lloyd A.R. Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection. PLoS Pathog. 2011, 7:e1002243.
21. Campo D.S., Dimitrova Z., Mitchell R.J., Lara J., Khudyakov Y. Coordinated evolution of the hepatitis C virus. Proc. Natl. Acad. Sci. USA 2008, 105:9685-9690.
22. Cannon N.A., Donlin M.J., Mayes L.M., Lyra A.C., Di Bisceglie A.M., Tavis J.E. Evidence for action of ribavirin through the hepatitis C virus RNA polymerase. J. Viral Hepatitis 2009, 16:595-604.
23. Canobio S., Guilbert C.M., Troesch M., Samson J., Lemay M., Pelletier V.A., Bernard-Bonnin A.C., Kozielski R., Lapointe N., Martin S.R., Soudeyns H. Differing patterns of liver disease progression and hepatitis C virus (HCV) quasispecies evolution in children vertically coinfected with HCV and human immunodeficiency virus type 1. J. Clin. Microbiol. 2004, 42:4365-4369.
24. Castera L., Hezode C., Roudot-Thoraval F., Lonjon I., Zafrani E.S., Pawlotsky J.M., Dhumeaux D. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut 2004, 53:420-424.
25. Chambers T.J., Fan X., Droll D.A., Hembrador E., Slater T., Nickells M.W., Dustin L.B., Di Bisceglie A.M. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. J. Virol. 2005, 79:3071-3083.
26. Chevaliez S., Bouvier-Alias M., Brillet R., Pawlotsky J.M. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS ONE 2009, 4:e8209.
27. Chevaliez S., Pawlotsky J.M. Virology of hepatitis C virus infection. Best Pract. Res. Clin. Gastroenterol. 2012, 26:381-389.
28. Cho E.J., Jeong S.H., Han B.H., Lee S.U., Yun B.C., Park E.T. Hepatitis C virus (HCV) genotypes and the influence of HCV subtype 1b on the progression of chronic hepatitis C in Korea: a single center experience. Clin. Mol. Hepatol. 2012, 18:219-224.
29. Choo Q.L., Kuo G., Weiner A.J., Overby L.R., Bradley D.W., Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244:359-362.
30. Ciotti M., Marcuccilli F., Guenci T., Babakir-Mina M., Chiodo F., Favarato M., Perno C.F. A multicenter evaluation of the Abbott RealTime HCV Genotype II assay. J. Virol. Methods 2010, 167:205-207.
31. Cox A.L., Mosbruger T., Lauer G.M., Pardoll D., Thomas D.L., Ray S.C. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology 2005, 42:104-112.
32. Cox A.L., Page K., Bruneau J., Shoukry N.H., Lauer G.M., Kim A.Y., Rosen H.R., Radziewicz H., Grakoui A., Fierer D.S., Branch A.D., Kaplan D.E., Chang K.M. Rare birds in North America: acute hepatitis C cohorts. Gastroenterology 2009, 136:26-31.
33. Cuevas J.M., Gonzalez-Candelas F., Moya A., Sanjuan R. Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo. J. Virol. 2009, 83:5760-5764.
34. Dietz J., Schelhorn S.E., Fitting D., Mihm U., Susser S., Welker M.W., Fuller C., Daumer M., Teuber G., Wedemeyer H., Berg T., Lengauer T., Zeuzem S., Herrmann E., Sarrazin C. Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients. J. Virol. 2013, 87:6172-6181.
35. Domingo E., Gomez J. Quasispecies and its impact on viral hepatitis. Virus Res. 2007, 127:131-150.
36. Domingo E., Martin V., Perales C., Grande-Perez A., Garcia-Arriaza J., Arias A. Viruses as quasispecies: biological implications. Quasispecies: Concepts and Implications for Virology 2006, 51-782. Springer. E. Domingo (Ed.).
37. Domingo E., Sabo D., Taniguchi T., Weissmann C. Nucleotide sequence heterogeneity of an RNA phage population. Cell 1978, 13:735-744.
38. Domingo E., Sheldon J., Perales C. Viral quasispecies evolution. Microbiol. Mol. Biol. Rev. 2012, 76:159-216.
39. Dong Z.X., Zhou H.J., Wang J.H., Xiang X.G., Zhuang Y., Guo S.M., Gui H.L., Zhao G.D., Tang W.L., Wang H., Xie Q. Distribution of hepatitis C virus genotypes in Chinese patients with chronic hepatitis C: correlation with patients' characteristics and clinical parameters. J. Dig. Dis. 2012, 13:564-570.
40. Drexler J.F., Corman V.M., Muller M.A., Lukashev A.N., Gmyl A., Coutard B., Adam A., Ritz D., Leijten L.M., van Riel D., Kallies R., Klose S.M., Gloza-Rausch F., Binger T., Annan A., Adu-Sarkodie Y., Oppong S., Bourgarel M., Rupp D., Hoffmann B., Schlegel M., Kummerer B.M., Kruger D.H., Schmidt-Chanasit J., Setien A.A., Cottontail V.M., Hemachudha T., Wacharapluesadee S., Osterrieder K., Bartenschlager R., Matthee S., Beer M., Kuiken T., Reusken C., Leroy E.M., Ulrich R.G., Drosten C. Evidence for novel hepaciviruses in rodents. PLoS Pathog. 2013, 9:e1003438.
41. Drummond A., Pybus O.G., Rambaut A. Inference of viral evolutionary rates from molecular sequences. Adv. Parasitol. 2003, 54:331-358.
42. Drummond A.J., Rambaut A. BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol. Biol. 2007, 7:214.
43. Ducoulombier D., Roque-Afonso A.M., Di Liberto G., Penin F., Kara R., Richard Y., Dussaix E., Feray C. Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes. Hepatology 2004, 39:817-825.
44. Duffy S., Shackelton L.A., Holmes E.C. Rates of evolutionary change in viruses: patterns and determinants. Nat. Rev. Genet. 2008, 9:267-276.
45. EASL EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J. Hepatol. 2011, 55:245-264.
46. Fan X., Mao Q., Zhou D., Lu Y., Xing J., Xu Y., Ray S.C., Di Bisceglie A.M. High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy. Hepatology 2009, 50:1765-1772.
47. Farci P. New insights into the HCV quasispecies and compartmentalization. Semin. Liver Dis. 2011, 31:356-374.
48. Farci P., Quinti I., Farci S., Alter H.J., Strazzera R., Palomba E., Coiana A., Cao D., Casadei A.M., Ledda R., Iorio R., Vegnente A., Diaz G., Tovo P.A. Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively. Proc. Natl. Acad. Sci. USA 2006, 103:8475-8480.
49. Farci P., Shimoda A., Coiana A., Diaz G., Peddis G., Melpolder J.C., Strazzera A., Chien D.Y., Munoz S.J., Balestrieri A., Purcell R.H., Alter H.J. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000, 288:339-344.
50. Farci P., Strazzera R., Alter H.J., Farci S., Degioannis D., Coiana A., Peddis G., Usai F., Serra G., Chessa L., Diaz G., Balestrieri A., Purcell R.H. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc. Natl. Acad. Sci. USA 2002, 99:3081-3086.
51. Feld J.J., Hoofnagle J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005, 436:967-972.
52. Figlerowicz M. Chronic Hepatitis C in Children - Clinical and Virological Factors Affecting Interferon Alpha or Interferon Alpha and Ribavirin Therapy 2005, Wydawnictwo Naukowe Akademii Medycznej im., Karola Marcinkowskiego w Poznaniu, Poznan.
53. Figlerowicz M., Alejska M., Kurzyńska-Kokorniak A., Figlerowicz M. Genetic variability: the key problem in the prevention and therapy of RNA-based virus infections. Med. Res. Rev. 2003, 23:488-518.
54. Figlerowicz M., Jackowiak P., Formanowicz P., Kedziora P., Alejska M., Malinowska N., Blazewicz J., Figlerowicz M. Hepatitis C virus quasispecies in chronically infected children subjected to interferon-ribavirin therapy. Arch. Virol. 2010, 155:1977-1987.
55. Fishman S.L., Branch A.D. The quasispecies nature and biological implications of the hepatitis C virus. Infect. Genet. Evol. 2009, 9:1158-1167.
56. Flamm S.L., Lawitz E., Jacobson I., Bourliere M., Hezode C., Vierling J.M., Bacon B.R., Niederau C., Sherman M., Goteti V., Sings H.L., Barnard R.O., Howe J.A., Pedicone L.D., Burroughs M.H., Brass C.A., Albrecht J.K., Poordad F. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin. Gastroenterol. Hepatol. 2013, 11:81-87. e84; quiz e85.
57. Flisiak R., Feinman S.V., Jablkowski M., Horban A., Kryczka W., Pawlowska M., Heathcote J.E., Mazzella G., Vandelli C., Nicolas-Metral V., Grosgurin P., Liz J.S., Scalfaro P., Porchet H., Crabbe R. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients. Hepatology 2009, 49:1460-1468.
58. Gane E.J., Stedman C.A., Hyland R.H., Ding X., Svarovskaia E., Symonds W.T., Hindes R.G., Berrey M.M. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 2013, 368:34-44.
59. Gao F., Bailes E., Robertson D.L., Chen Y., Rodenburg C.M., Michael S.F., Cummins L.B., Arthur L.O., Peeters M., Shaw G.M., Sharp P.M., Hahn B.H. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 1999, 397:436-441.
60. Garcia-Monzon C., Jara P., Fernandez-Bermejo M., Hierro L., Frauca E., Camarena C., Diaz C., De la Vega A., Larrauri J., Garcia-Iglesias C., Borque M.J., Sanz P., Garcia-Buey L., Moreno-Monteagudo J.A., Moreno-Otero R. Chronic hepatitis C in children: a clinical and immunohistochemical comparative study with adult patients. Hepatology 1998, 28:1696-1701.
61. Gerotto M., Resti M., Dal Pero F., Migliorato I., Alberti A., Bortolotti F. Evolution of hepatitis C virus quasispecies in children with chronic hepatitis C. Infection 2006, 34:62-65.
62. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
63. Gismondi M.I., Becker P.D., Diaz Carrasco J.M., Guzman C.A., Campos R.H., Preciado M.V. Evolution of hepatitis C virus hypervariable region 1 in immunocompetent children born to HCV-infected mothers. J. Viral Hepatitis 2009, 16:332-339.
64. Go E.P., Hewawasam G., Liao H.X., Chen H., Ping L.H., Anderson J.A., Hua D.C., Haynes B.F., Desaire H. Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry. J. Virol. 2011, 85:8270-8284.
65. Gonzalez-Candelas F., Lopez-Labrador F.X., Bracho M.A. Recombination in hepatitis C virus. Viruses 2011, 3:2006-2024.
66. Gonzalez V., Gomes-Fernandes M., Bascunana E., Casanovas S., Saludes V., Jordana-Lluch E., Matas L., Ausina V., Martro E. Accuracy of a commercially available assay for HCV genotyping and subtyping in the clinical practice. J. Clin. Virol. 2013, 58:249-253.
67. Gray R.R., Parker J., Lemey P., Salemi M., Katzourakis A., Pybus O.G. The mode and tempo of hepatitis C virus evolution within and among hosts. BMC Evol. Biol. 2011, 11:131.
68. Gutierrez S., Michalakis Y., Blanc S. Virus population bottlenecks during within-host progression and host-to-host transmission. Curr Opin Virol 2012, 2:546-555.
69. Hnatyszyn H.J. Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes. Antivir. Ther. 2005, 10:1-11.
70. Hofmann W.P., Polta A., Herrmann E., Mihm U., Kronenberger B., Sonntag T., Lohmann V., Schonberger B., Zeuzem S., Sarrazin C. Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. Gastroenterology 2007, 132:921-930.
71. Holmes E.C. Does hepatitis C virus really form quasispecies?. Infect. Genet. Evol. 2010, 10:431-432.
72. Holmes E.C., Moya A. Is the quasispecies concept relevant to RNA viruses?. J. Virol. 2002, 76:460-465.
73. Hong S.K., Cho S.I., Ra E.K., Kim E.C., Park J.S., Park S.S., Seong M.W. Evaluation of two hepatitis C virus genotyping assays based on the 5' untranslated region (UTR): the limitations of 5' UTR-based assays and the need for a supplementary sequencing-based approach. J. Clin. Microbiol. 2012, 50:3741-3743.
74. Jackowiak P., Figlerowicz M., Kurzynska-Kokorniak A., Figlerowicz M. Mechanisms involved in the development of chronic hepatitis C as potential targets of antiviral therapy. Curr. Pharm. Biotechnol. 2011, 12:1774-1780.
75. Jackowiak P., Kowala-Piaskowska A., Figlerowicz M., Alejska M., Malinowska N., Figlerowicz M. Evolution of hepatitis C virus hypervariable region 1 in chronically infected children. Virus Res. 2012, 167:380-384.
76. Jacobson I.M., McHutchison J.G., Dusheiko G., Di Bisceglie A.M., Reddy K.R., Bzowej N.H., Marcellin P., Muir A.J., Ferenci P., Flisiak R., George J., Rizzetto M., Shouval D., Sola R., Terg R.A., Yoshida E.M., Adda N., Bengtsson L., Sankoh A.J., Kieffer T.L., George S., Kauffman R.S., Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011, 364:2405-2416.
77. Janssen H.L., Reesink H.W., Lawitz E.J., Zeuzem S., Rodriguez-Torres M., Patel K., van der Meer A.J., Patick A.K., Chen A., Zhou Y., Persson R., King B.D., Kauppinen S., Levin A.A., Hodges M.R. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 2013, 368:1685-1694.
78. Jardim A.C., Bittar C., Matos R.P., Yamasaki L.H., Silva R.A., Pinho J.R., Fachini R.M., Carareto C.M., de Carvalho-Mello I.M., Rahal P. Analysis of HCV quasispecies dynamic under selective pressure of combined therapy. BMC Infect. Dis. 2013, 13:61.
79. Jopling C.L., Yi M., Lancaster A.M., Lemon S.M., Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005, 309:1577-1581.
80. Jung Y.K., Kim J.H. Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?. Clin. Mol. Hepatol. 2013, 19:26-28.
81. Kageyama S., Agdamag D.M., Alesna E.T., Leano P.S., Heredia A.M., Abellanosa-Tac-An I.P., Jereza L.D., Tanimoto T., Yamamura J., Ichimura H. A natural inter-genotypic (2b/1b) recombinant of hepatitis C virus in the Philippines. J. Med. Virol. 2006, 78:1423-1428.
82. Kalinina O., Norder H., Magnius L.O. Full-length open reading frame of a recombinant hepatitis C virus strain from St Petersburg: proposed mechanism for its formation. J. Gen. Virol. 2004, 85:1853-1857.
83. Kalinina O., Norder H., Mukomolov S., Magnius L.O. A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. J. Virol. 2002, 76:4034-4043.
84. Kamal S.M., Nasser I.A. Hepatitis C genotype 4: what we know and what we don't yet know. Hepatology 2008, 47:1371-1383.
85. Kang M.J., Jung E.U., Park S.W., Choi P., Kim J.H., Park S.J., Park E.T., Lee Y.J., Lee S.H., Seol S.Y. Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection. Korean J. Hepatol. 2008, 14:318-330.
86. Kapoor A., Simmonds P., Gerold G., Qaisar N., Jain K., Henriquez J.A., Firth C., Hirschberg D.L., Rice C.M., Shields S., Lipkin W.I. Characterization of a canine homolog of hepatitis C virus. Proc. Natl. Acad. Sci. USA 2011, 108:11608-11613.
87. Kapoor A., Simmonds P., Scheel T.K., Hjelle B., Cullen J.M., Burbelo P.D., Chauhan L.V., Duraisamy R., Sanchez Leon M., Jain K., Vandegrift K.J., Calisher C.H., Rice C.M., Lipkin W.I. Identification of rodent homologs of hepatitis C virus and pegiviruses. MBio 2013, 4:e00216-00213.
88. Kato N., Nakamura T., Dansako H., Namba K., Abe K., Nozaki A., Naka K., Ikeda M., Shimotohno K. Genetic variation and dynamics of hepatitis C virus replicons in long-term cell culture. J. Gen. Virol. 2005, 86:645-656.
89. Keam S.J., Cvetkovic R.S. Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C mono-infection. Drugs 2008, 68:1273-1317.
90. Kieffer T.L., De Meyer S., Bartels D.J., Sullivan J.C., Zhang E.Z., Tigges A., Dierynck I., Spanks J., Dorrian J., Jiang M., Adiwijaya B., Ghys A., Beumont M., Kauffman R.S., Adda N., Jacobson I.M., Sherman K.E., Zeuzem S., Kwong A.D., Picchio G. Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS ONE 2012, 7:e34372.
91. Kiprijanovska S., Davalieva K., Noveski P., Sukarova-Stefanovska E., Plaseska-Karanfilska D. Prevalence of hepatitis C virus genotypes in risk groups in the Republic of Macedonia: a 5years survey. J. Med. Virol. 2013, 85:2072-2078.
92. Kuiken C., Simmonds P. Nomenclature and numbering of the hepatitis C virus. Methods Mol. Biol. 2009, 510:33-53.
93. Kuntzen T., Timm J., Berical A., Lewis-Ximenez L.L., Jones A., Nolan B., Schulze zur Wiesch J., Li B., Schneidewind A., Kim A.Y., Chung R.T., Lauer G.M., Allen T.M. Viral sequence evolution in acute hepatitis C virus infection. J. Virol. 2007, 81:11658-11668.
94. Lamarre D., Anderson P.C., Bailey M., Beaulieu P., Bolger G., Bonneau P., Bos M., Cameron D.R., Cartier M., Cordingley M.G., Faucher A.M., Goudreau N., Kawai S.H., Kukolj G., Lagace L., LaPlante S.R., Narjes H., Poupart M.A., Rancourt J., Sentjens R.E., St George R., Simoneau B., Steinmann G., Thibeault D., Tsantrizos Y.S., Weldon S.M., Yong C.L., Llinas-Brunet M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003, 426:186-189.
95. Lange C.M., Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J. Hepatol. 2012, 58:583-592.
96. Lara J., Tavis J.E., Donlin M.J., Lee W.M., Yuan H.J., Pearlman B.L., Vaughan G., Forbi J.C., Xia G.L., Khudyakov Y.E. Coordinated evolution among hepatitis C virus genomic sites is coupled to host factors and resistance to interferon. In Silico Biol. 2012, 11:213-224.
97. Laskus T., Wilkinson J., Gallegos-Orozco J.F., Radkowski M., Adair D.M., Nowicki M., Operskalski E., Buskell Z., Seeff L.B., Vargas H., Rakela J. Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion. Gastroenterology 2004, 127:764-776.
98. Lauck M., Sibley S.D., Lara J., Purdy M.A., Khudyakov Y., Hyeroba D., Tumukunde A., Weny G., Switzer W.M., Chapman C.A., Hughes A.L., Friedrich T.C., O'Connor D.H., Goldberg T.L. A novel hepacivirus with an unusually long and intrinsically disordered NS5A protein in a wild Old World primate. J. Virol. 2013, 87:8971-8981.
99. Legrand-Abravanel F., Claudinon J., Nicot F., Dubois M., Chapuy-Regaud S., Sandres-Saune K., Pasquier C., Izopet J. New natural intergenotypic (2/5) recombinant of hepatitis C virus. J. Virol. 2007, 81:4357-4362.
100. Lemey P., Rambaut A., Drummond A.J., Suchard M.A. Bayesian phylogeography finds its roots. PLoS Comput. Biol. 2009, 5:e1000520.
101. Leone F., Zylberberg H., Squadrito G., Le Guen B., Berthelot P., Pol S., Brechot C. Hepatitis C virus (HCV) hypervariable region 1 complexity does not correlate with severity of liver disease, HCV type, viral load or duration of infection. J. Hepatol. 1998, 29:689-694.
102. Lesburg C.A., Cable M.B., Ferrari E., Hong Z., Mannarino A.F., Weber P.C. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat. Struct. Biol. 1999, 6:937-943.
103. Li H., Hughes A.L., Bano N., McArdle S., Livingston S., Deubner H., McMahon B.J., Townshend-Bulson L., McMahan R., Rosen H.R., Gretch D.R. Genetic diversity of near genome-wide hepatitis C virus sequences during chronic infection: evidence for protein structural conservation over time. PLoS ONE 2011, 6:e19562.
104. Li H., Stoddard M.B., Wang S., Blair L.M., Giorgi E.E., Parrish E.H., Learn G.H., Hraber P., Goepfert P.A., Saag M.S., Denny T.N., Haynes B.F., Hahn B.H., Ribeiro R.M., Perelson A.S., Korber B.T., Bhattacharya T., Shaw G.M. Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. PLoS Pathog. 2012, 8:e1002880.
105. Lindenbach B.D., Thiel H.-J., Rice C.M. Flaviviridae: the viruses and their replication. Fields Virology 2007, 1101-1151. Lippincott-Raven Publishers, Philadelphia. 5th ed. D.M. Knipe, P.M. Howley (Eds.).
106. Liu L., Fisher B.E., Thomas D.L., Cox A.L., Ray S.C. Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology 2012, 55:1684-1691.
107. Lohmann V., Korner F., Dobierzewska A., Bartenschlager R. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J. Virol. 2001, 75:1437-1449.
108. Lopez-Labrador F.X., Ampurdanes S., Gimenez-Barcons M., Guilera M., Costa J., Jimenez de Anta M.T., Sanchez-Tapias J.M., Rodes J., Saiz J.C. Relationship of the genomic complexity of hepatitis C virus with liver disease severity and response to interferon in patients with chronic HCV genotype 1b infection [correction of interferon]. Hepatology 1999, 29:897-903.
109. Luciani F., Alizon S. The evolutionary dynamics of a rapidly mutating virus within and between hosts: the case of hepatitis C virus. PLoS Comput. Biol. 2009, 5:e1000565.
110. Lutchman G., Danehower S., Song B.C., Liang T.J., Hoofnagle J.H., Thomson M., Ghany M.G. Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology 2007, 132:1757-1766.
111. Lyons S., Kapoor A., Sharp C., Schneider B.S., Wolfe N.D., Culshaw G., Corcoran B., McGorum B.C., Simmonds P. Nonprimate hepaciviruses in domestic horses, United kingdom. Emerg. Infect. Dis. 2012, 18:1976-1982.
112. Machlin E.S., Sarnow P., Sagan S.M. Masking the 5' terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex. Proc. Natl. Acad. Sci. USA 2011, 108:3193-3198.
113. Maggi F., Fornai C., Vatteroni M.L., Giorgi M., Morrica A., Pistello M., Cammarota G., Marchi S., Ciccorossi P., Bionda A., Bendinelli M. Differences in hepatitis C virus quasispecies composition between liver, peripheral blood mononuclear cells and plasma. J. Gen. Virol. 1997, 78(Pt 7):1521-1525.
114. Magiorkinis G., Magiorkinis E., Paraskevis D., Ho S.Y., Shapiro B., Pybus O.G., Allain J.P., Hatzakis A. The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis. PLoS Med. 2009, 6:e1000198.
115. Mania A., Kemnitz P., Figlerowicz M., Mozer-Lisewska I., Kowala-Piaskowska A., Woźniak A., Służewski W. Clinical picture and liver histology of chronic hepatitis C in children. Infect. Dis. Clin. Pract. 2012, 20:141-147.
116. Markov P.V., Pepin J., Frost E., Deslandes S., Labbe A.C., Pybus O.G. Phylogeography and molecular epidemiology of hepatitis C virus genotype 2 in Africa. J. Gen. Virol. 2009, 90:2086-2096.
117. McHutchison J.G., Everson G.T., Gordon S.C., Jacobson I.M., Sulkowski M., Kauffman R., McNair L., Alam J., Muir A.J. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 2009, 360:1827-1838.
118. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., Goodman Z.D., Ling M.H., Cort S., Albrecht J.K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1998, 339:1485-1492.
119. Miura M., Maekawa S., Takano S., Komatsu N., Tatsumi A., Asakawa Y., Shindo K., Amemiya F., Nakayama Y., Inoue T., Sakamoto M., Yamashita A., Moriishi K., Enomoto N. Deep sequencing analysis of the association between the quasispecies nature of the hepatitis c virus core region and disease progression 2013, J. Virol.
120. Moradpour D., Penin F., Rice C.M. Replication of hepatitis C virus. Nat. Rev. Microbiol. 2007, 5:453-463.
121. Moreau I., Levis J., Crosbie O., Kenny-Walsh E., Fanning L.J. Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a. Virol. J. 2008, 5:78.
122. Morel V., Fournier C., Francois C., Brochot E., Helle F., Duverlie G., Castelain S. Genetic recombination of the hepatitis C virus: clinical implications. J. Viral Hepatitis 2011, 18:77-83.
123. Moya A., Elena S.F., Bracho A., Miralles R., Barrio E. The evolution of RNA viruses: a population genetics view. Proc. Natl. Acad. Sci. USA 2000, 97:6967-6973.
124. Nasu A., Marusawa H., Ueda Y., Nishijima N., Takahashi K., Osaki Y., Yamashita Y., Inokuma T., Tamada T., Fujiwara T., Sato F., Shimizu K., Chiba T. Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing. PLoS ONE 2011, 6:e24907.
125. Netski D.M., Mosbruger T., Depla E., Maertens G., Ray S.C., Hamilton R.G., Roundtree S., Thomas D.L., McKeating J., Cox A. Humoral immune response in acute hepatitis C virus infection. Clin. Infect. Dis. 2005, 41:667-675.
126. Neumann A.U., Lam N.P., Dahari H., Gretch D.R., Wiley T.E., Layden T.J., Perelson A.S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282:103-107.
127. Ninomiya M., Ueno Y., Funayama R., Nagashima T., Nishida Y., Kondo Y., Inoue J., Kakazu E., Kimura O., Nakayama K., Shimosegawa T. Use of illumina deep sequencing technology to differentiate hepatitis C virus variants. J. Clin. Microbiol. 2012, 50:857-866.
128. Njouom R., Caron M., Besson G., Ndong-Atome G.R., Makuwa M., Pouillot R., Nkoghe D., Leroy E., Kazanji M. Phylogeography, risk factors and genetic history of hepatitis C virus in Gabon, central Africa. PLoS ONE 2012, 7:e42002.
129. Noppornpanth S., Lien T.X., Poovorawan Y., Smits S.L., Osterhaus A.D., Haagmans B.L. Identification of a naturally occurring recombinant genotype 2/6 hepatitis C virus. J. Virol. 2006, 80:7569-7577.
130. Noppornpanth S., Sablon E., De Nys K., Truong X.L., Brouwer J., Van Brussel M., Smits S.L., Poovorawan Y., Osterhaus A.D., Haagmans B.L. Genotyping hepatitis C viruses from Southeast Asia by a novel line probe assay that simultaneously detects core and 5' untranslated regions. J. Clin. Microbiol. 2006, 44:3969-3974.
131. Ogata N., Alter H.J., Miller R.H., Purcell R.H. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc. Natl. Acad. Sci. USA 1991, 88:3392-3396.
132. Ohtsuru S., Ueda Y., Marusawa H., Inuzuka T., Nishijima N., Nasu A., Shimizu K., Koike K., Uemoto S., Chiba T. Dynamics of defective hepatitis C virus clones in reinfected liver grafts in liver transplant recipients; ultra-deep sequencing analysis 2013, J. Clin. Microbiol.
133. Okuda M., Hino K., Korenaga M., Yamaguchi Y., Katoh Y., Okita K. Differences in hypervariable region 1 quasispecies of hepatitis C virus in human serum, peripheral blood mononuclear cells, and liver. Hepatology 1999, 29:217-222.
134. Pang P.S., Planet P.J., Glenn J.S. The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. PLoS ONE 2009, 4:e6579.
135. Park S.Y., Rim M.Y., Yo I.K., Ha M.S., Kim J.S., Lee J.W., Jung Y.K., Kwon O.S., Kim Y.S., Choi D.J., Kim J.H. Efficacy of peginterferon and ribavirin combination therapy of chronic hepatitis C: a pooled analysis. Korean J. Gastroenterol. 2012, 60:306-314.
136. Pawlotsky J.M. Hepatitis C virus genetic variability: pathogenic and clinical implications. Clin. Liver Dis. 2003, 7:45-66.
137. Pawlotsky J.M. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011, 53:1742-1751.
138. Pawlotsky J.M., Germanidis G., Neumann A.U., Pellerin M., Frainais P.O., Dhumeaux D. Interferon resistance of hepatitis C virus genotype 1b: relationship to nonstructural 5A gene quasispecies mutations. J. Virol. 1998, 72:2795-2805.
139. Pawlotsky J.M., Pellerin M., Bouvier M., Roudot-Thoraval F., Germanidis G., Bastie A., Darthuy F., Remire J., Soussy C.J., Dhumeaux D. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C. J. Med. Virol. 1998, 54:256-264.
140. Perelson A.S., Ribeiro R.M. Mutagenic effects of ribavirin in vivo. J. Hepatol. 2005, 43:553-555.
141. Perry C.M. Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C. Drugs 2012, 72:619-641.
142. Petruzziello A., Coppola N., Diodato A.M., Iervolino V., Azzaro R., Di Costanzo G., Di Macchia C.A., Di Meo T., Loquercio G., Pasquale G., Cacciapuoti C. Age and gender distribution of hepatitis C virus genotypes in the metropolitan area of Naples. Intervirology 2013, 56:206-212.
143. Pfafferott K., Gaudieri S., Ulsenheimer A., James I., Heeg M., Nolan D., John M., Rauch A., Mallal S., Lucas A., Klenerman P., Diepolder H.M., Lucas M. Constrained pattern of viral evolution in acute and early HCV infection limits viral plasticity. PLoS ONE 2011, 6:e16797.
144. Pollicita M., Cento V., Paba P., Perno C.F., Ciotti M. Nucleotide polymorphisms in the 5'-UTR region of HCV can affect the ability of two widely used assays to assign an HCV genotype. J. Virol. Methods 2013, 193:205-208.
145. Poordad F., McCone J., Bacon B.R., Bruno S., Manns M.P., Sulkowski M.S., Jacobson I.M., Reddy K.R., Goodman Z.D., Boparai N., DiNubile M.J., Sniukiene V., Brass C.A., Albrecht J.K., Bronowicki J.P. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011, 364:1195-1206.
146. Powdrill M.H., Tchesnokov E.P., Kozak R.A., Russell R.S., Martin R., Svarovskaia E.S., Mo H., Kouyos R.D., Gotte M. Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. Proc. Natl. Acad. Sci. USA 2011, 108:20509-20513.
147. Probst A., Dang T., Bochud M., Egger M., Negro F., Bochud P.Y. Role of hepatitis C virus genotype 3 in liver fibrosis progression-a systematic review and meta-analysis. J. Viral Hepatitis 2011, 18:745-759.
148. Puig-Basagoiti F., Forns X., Furcic I., Ampurdanes S., Gimenez-Barcons M., Franco S., Sanchez-Tapias J.M., Saiz J.C. Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C. J. Gen. Virol. 2005, 86:1067-1075.
149. Pybus O.G., Barnes E., Taggart R., Lemey P., Markov P.V., Rasachak B., Syhavong B., Phetsouvanah R., Sheridan I., Humphreys I.S., Lu L., Newton P.N., Klenerman P. Genetic history of hepatitis C virus in East Asia. J. Virol. 2009, 83:1071-1082.
150. Pybus O.G., Charleston M.A., Gupta S., Rambaut A., Holmes E.C., Harvey P.H. The epidemic behavior of the hepatitis C virus. Science 2001, 292:2323-2325.
151. Pybus O.G., Rambaut A. Evolutionary analysis of the dynamics of viral infectious disease. Nat. Rev. Genet. 2009, 10:540-550.
152. Quan P.L., Firth C., Conte J.M., Williams S.H., Zambrana-Torrelio C.M., Anthony S.J., Ellison J.A., Gilbert A.T., Kuzmin I.V., Niezgoda M., Osinubi M.O., Recuenco S., Markotter W., Breiman R.F., Kalemba L., Malekani J., Lindblade K.A., Rostal M.K., Ojeda-Flores R., Suzan G., Davis L.B., Blau D.M., Ogunkoya A.B., Alvarez Castillo D.A., Moran D., Ngam S., Akaibe D., Agwanda B., Briese T., Epstein J.H., Daszak P., Rupprecht C.E., Holmes E.C., Lipkin W.I. Bats are a major natural reservoir for hepaciviruses and pegiviruses. Proc.Natl. Acad. Sci. USA 2013, 110:8194-8199.
153. Quesnel-Vallieres M., Lemay M., Lapointe N., Martin S.R., Soudeyns H. HCV quasispecies evolution during treatment with interferon alfa-2b and ribavirin in two children coinfected with HCV and HIV-1. J. Clin. Virol. 2008, 43:236-240.
154. Quinkert D., Bartenschlager R., Lohmann V. Quantitative analysis of the hepatitis C virus replication complex. J. Virol. 2005, 79:13594-13605.
155. Raimondi S., Bruno S., Mondelli M.U., Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J. Hepatol. 2009, 50:1142-1154.
156. Ramachandran S., Campo D.S., Dimitrova Z.E., Xia G.L., Purdy M.A., Khudyakov Y.E. Temporal variations in the hepatitis C virus intrahost population during chronic infection. J. Virol. 2011, 85:6369-6380.
157. Ranjith-Kumar C.T., Sarisky R.T., Gutshall L., Thomson M., Kao C.C. De novo initiation pocket mutations have multiple effects on hepatitis C virus RNA-dependent RNA polymerase activities. J. Virol. 2004, 78:12207-12217.
158. Rao G.S., Molleston J.P. Children with hepatitis C. Curr. Gastroenterol. Rep. 2005, 7:37-44.
159. Ray S.C., Arthur R.R., Carella A., Bukh J., Thomas D.L. Genetic epidemiology of hepatitis C virus throughout Egypt. J. Infect. Dis. 2000, 182:698-707.
160. Revie D., Salahuddin S.Z. Human cell types important for hepatitis C virus replication in vivo and in vitro: old assertions and current evidence. Virol. J. 2011, 8:346.
161. Ribeiro R.M., Li H., Wang S., Stoddard M.B., Learn G.H., Korber B.T., Bhattacharya T., Guedj J., Parrish E.H., Hahn B.H., Shaw G.M., Perelson A.S. Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog. 2012, 8:e1002881.
162. Robertson B.H. Viral hepatitis and primates: historical and molecular analysis of human and nonhuman primate hepatitis A, B, and the GB-related viruses. J. Viral Hepatitis 2001, 8:233-242.
163. Rothman A.L., Morishima C., Bonkovsky H.L., Polyak S.J., Ray R., Di Bisceglie A.M., Lindsay K.L., Malet P.F., Chang M., Gretch D.R., Sullivan D.G., Bhan A.K., Wright E.C., Koziel M.J. Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology 2005, 41:617-625.
164. Ruiz-Moreno M., Leal-Orozco A., Millan A. Hepatitis C virus infection in children. J. Hepatol. 1999, 31(Suppl. 1):124-129.
165. Sagan S.M., Sarnow P., Wilson J.A. Modulation of GB virus B RNA abundance by microRNA-122: dependence on and escape from microRNA-122 restriction. J. Virol. 2013, 87:7338-7347.
166. Salemi M., Vandamme A.M. Hepatitis C virus evolutionary patterns studied through analysis of full-genome sequences. J. Mol. Evol. 2002, 54:62-70.
167. Saludes V., Bracho M.A., Valero O., Ardevol M., Planas R., Gonzalez-Candelas F., Ausina V., Martro E. Baseline prediction of combination therapy outcome in hepatitis C virus 1b infected patients by discriminant analysis using viral and host factors. PLoS ONE 2010, 5:e14132.
168. Sandres K., Dubois M., Pasquier C., Payen J.L., Alric L., Duffaut M., Vinel J.P., Pascal J.P., Puel J., Izopet J. Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy. J. Virol. 2000, 74:661-668.
169. Sanjuan R., Nebot M.R., Chirico N., Mansky L.M., Belshaw R. Viral mutation rates. J. Virol. 2010, 84:9733-9748.
170. Sarrazin C., Kieffer T.L., Bartels D., Hanzelka B., Muh U., Welker M., Wincheringer D., Zhou Y., Chu H.M., Lin C., Weegink C., Reesink H., Zeuzem S., Kwong A.D. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007, 132:1767-1777.
171. Schaller T., Appel N., Koutsoudakis G., Kallis S., Lohmann V., Pietschmann T., Bartenschlager R. Analysis of hepatitis C virus superinfection exclusion by using novel fluorochrome gene-tagged viral genomes. J. Virol. 2007, 81:4591-4603.
172. Scheel T.K., Galli A., Li Y.P., Mikkelsen L.S., Gottwein J.M., Bukh J. Productive homologous and non-homologous recombination of hepatitis C virus in cell culture. PLoS Pathog. 2013, 9:e1003228.
173. Sentandreu V., Jimenez-Hernandez N., Torres-Puente M., Bracho M.A., Valero A., Gosalbes M.J., Ortega E., Moya A., Gonzalez-Candelas F. Evidence of recombination in intrapatient populations of hepatitis C virus. PLoS ONE 2008, 3:e3239.
174. Shepherd J., Brodin H., Cave C., Waugh N., Price A., Gabbay J. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol. Assess. 2004, 8(Iii-iv):1-125.
175. Shi W., Freitas I.T., Zhu C., Zheng W., Hall W.W., Higgins D.G. Recombination in hepatitis C virus: identification of four novel naturally occurring inter-subtype recombinants. PLoS ONE 2012, 7:e41997.
176. Shimakami T., Yamane D., Jangra R.K., Kempf B.J., Spaniel C., Barton D.J., Lemon S.M. Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex. Proc. Natl. Acad. Sci. USA 2012, 109:941-946.
177. Shinol R.C., Gale H.B., Kan V.L. Performance of the Abbott RealTime HCV Genotype II RUO assay. J. Clin. Microbiol. 2012, 50:3099-3101.
178. Sibal A., Mishra D., Arora M. Hepatitis C in childhood. J. Indian Med. Assoc. 2002, 100:93-98.
179. Simmonds P. Clinical relevance of hepatitis C virus genotypes. Gut 1997, 40:291-293.
180. Simmonds P. The origin and evolution of hepatitis viruses in humans. J. Gen. Virol. 2001, 82:693-712.
181. Simmonds P. Genetic diversity and evolution of hepatitis C virus-15years on. J. Gen. Virol. 2004, 85:3173-3188.
182. Simmonds P. The origin of hepatitis C virus. Curr. Top. Microbiol. Immunol. 2013, 369:1-15.
183. Smith D.B., Bukh J., Kuiken C., Muerhoff A.S., Rice C.M., Stapleton J.T., Simmonds P. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes, updated criteria and assignment web resource. Hepatology 2013, 10.1002/hep.26744.
184. Sohn Y.H., Ko S.Y., Kim M.H., Oh H.B. Performance evaluation of the Abbott RealTime HCV Genotype II for hepatitis C virus genotyping. Clin. Chem. Lab. Med. 2010, 48:469-474.
185. Stapleton J.T., Foung S., Muerhoff A.S., Bukh J., Simmonds P. The GB viruses: a review and proposed classification of GBV-A, GBV-C (HGV), and GBV-D in genus Pegivirus within the family Flaviviridae. J. Gen. Virol. 2011, 92:233-246.
186. Susser S., Vermehren J., Forestier N., Welker M.W., Grigorian N., Fuller C., Perner D., Zeuzem S., Sarrazin C. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J. Clin. Virol. 2011, 52:321-327.
187. Tamura K., Peterson D., Peterson N., Stecher G., Nei M., Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 2011, 28:2731-2739.
188. Torres-Puente M., Cuevas J.M., Jimenez-Hernandez N., Bracho M.A., Garcia-Robles I., Carnicer F., del Olmo J., Ortega E., Moya A., Gonzalez-Candelas F. Contribution of insertions and deletions to the variability of hepatitis C virus populations. J. Gen. Virol. 2007, 88:2198-2203.
189. Tscherne D.M., Evans M.J., von Hahn T., Jones C.T., Stamataki Z., McKeating J.A., Lindenbach B.D., Rice C.M. Superinfection exclusion in cells infected with hepatitis C virus. J. Virol. 2007, 81:3693-3703.
190. Ueda E., Enomoto N., Sakamoto N., Hamano K., Sato C., Izumi N., Watanabe M. Changes of HCV quasispecies during combination therapy with interferon and ribavirin. Hepatol. Res. 2004, 29:89-96.
191. Urbanowicz A., Alejska M., Formanowicz P., Blazewicz J., Figlerowicz M., Bujarski J.J. Homologous crossovers among molecules of brome mosaic bromovirus RNA1 or RNA2 segments in vivo. J. Virol. 2005, 79:5732-5742.
192. Vaghefi P., Marchadier E., Dussaix E., Roque-Afonso A.M. Hepatitis C virus genotyping: comparison of the Abbott RealTime HCV Genotype II assay and NS5B sequencing. Pathol. Biol. (Paris) 2010, 58:175-178.
193. Vallet S., Gouriou S., Nkontchou G., Hotta H., Vilerio M., Legrand-Quillien M.C., Beaugrand M., Trinchet J.C., Nousbaum J.B., Deny P., Gaudy C., Goudeau A., Picard B., Payan C. Is hepatitis C virus NS3 protease quasispecies heterogeneity predictive of progression from cirrhosis to hepatocellular carcinoma?. J. Viral Hepatitis 2007, 14:96-106.
194. van de Laar T., Pybus O., Bruisten S., Brown D., Nelson M., Bhagani S., Vogel M., Baumgarten A., Chaix M.L., Fisher M., Gotz H., Matthews G.V., Neifer S., White P., Rawlinson W., Pol S., Rockstroh J., Coutinho R., Dore G.J., Dusheiko G.M., Danta M. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 2009, 136:1609-1617.
195. Vargas H.E., Laskus T., Radkowski M., Wilkinson J., Balan V., Douglas D.D., Harrison M.E., Mulligan D.C., Olden K., Adair D., Rakela J. Detection of hepatitis C virus sequences in brain tissue obtained in recurrent hepatitis C after liver transplantation. Liver Transpl. 2002, 8:1014-1019.
196. Verbeeck J., Maes P., Lemey P., Pybus O.G., Wollants E., Song E., Nevens F., Fevery J., Delport W., Van der Merwe S., Van Ranst M. Investigating the origin and spread of hepatitis C virus genotype 5a. J. Virol. 2006, 80:4220-4226.
197. Verbeeck J., Stanley M.J., Shieh J., Celis L., Huyck E., Wollants E., Morimoto J., Farrior A., Sablon E., Jankowski-Hennig M., Schaper C., Johnson P., Van Ranst M., Van Brussel M. Evaluation of Versant hepatitis C virus genotype assay (LiPA) 2.0. J. Clin. Microbiol. 2008, 46:1901-1906.
198. Verbinnen T., Van Marck H., Vandenbroucke I., Vijgen L., Claes M., Lin T.I., Simmen K., Neyts J., Fanning G., Lenz O. Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing. J. Virol. 2010, 84:11124-11133.
199. Vermehren J., Sarrazin C. New HCV therapies on the horizon. Clin. Microbiol. Infect. 2011, 17:122-134.
200. Viazov S., Widell A., Nordenfelt E. Mixed infection with two types of hepatitis C virus is probably a rare event. Infection 2000, 28:21-25.
201. Wang G.P., Sherrill-Mix S.A., Chang K.M., Quince C., Bushman F.D. Hepatitis C virus transmission bottlenecks analyzed by deep sequencing. J. Virol. 2010, 84:6218-6228.
202. Webster B., Wissing S., Herker E., Ott M., Greene W.C. Rapid intracellular competition between hepatitis C viral genomes as a result of mitosis. J. Virol. 2013, 87:581-596.
203. WHO, 2012. Hepatitis C. Fact sheet N°164 July 2012.
204. Xu Z., Fan X., Xu Y., Di Bisceglie A.M. Comparative analysis of nearly full-length hepatitis C virus quasispecies from patients experiencing viral breakthrough during antiviral therapy: clustered mutations in three functional genes, E2, NS2, and NS5a. J. Virol. 2008, 82:9417-9424.
205. Yan Z., Fan K., Wang Y., Fan Y., Tan Z., Deng G. Changing pattern of clinical epidemiology on hepatitis C virus infection in southwest china. Hepat. Mon. 2012, 12:196-204.
206. Yuan M., Lu T., Li C., Lu L. The evolutionary rates of HCV estimated with subtype 1a and 1b sequences over the ORF length and in different genomic regions. PLoS ONE 2013, 8:e64698.
207. Zein N.N. Clinical significance of hepatitis C virus genotypes. Clin. Microbiol. Rev. 2000, 13:223-235.
208. Zeuzem S. Treatment of hepatitis C virus infection. Praxis (Bern 1994) 2005, 94:721-726.